

找到约 47,800 条结果 (用时 0.55 秒)

### Clinical benefit and tolerability of adjuvant intraperitoneal ...

[ascopubs.org/doi/abs/10.1200/JCO.2016.34.15\\_suppl.e17054](https://ascopubs.org/doi/abs/10.1200/JCO.2016.34.15_suppl.e17054) - 翻译此页

作者: T Meghal - 2016

2017年5月11日 - ... in **patients** who **received** neoadjuvant treatment for **advanced ovarian cancer**. ... **Neoadjuvant chemotherapy** followed by interim surgery and **adjuvant chemotherapy** has demonstrated the same **benefit** as **adjuvant** treatment alone; ... evaluated our **patients** with stage III and IV **ovarian cancer** who **received** ...

### In the Neoadjuvant Era, Intraperitoneal Chemotherapy Is of Benefit in ...

[www.ascopost.com/.../in-the-neoadjuvant-era-intraperitoneal-chemotherapy-...](http://www.ascopost.com/.../in-the-neoadjuvant-era-intraperitoneal-chemotherapy-...) ▼ 翻译此页

2016年6月25日 - In the Neoadjuvant Era, **Intraperitoneal Chemotherapy Is of Benefit** in **Advanced** ... We wanted to determine if **patients** who **received** **neoadjuvant chemotherapy** **benefit** from IP ... To date, **tolerability** of IP cisplatin-based regimens **has** been one barrier to the ... IP Chemotherapy in **Advanced Ovarian Cancer**.

### Debate Over Intraperitoneal Chemotherapy in Newly Diagnosed ...

[www.ascopost.com/.../debate-over-intraperitoneal-chemotherapy-in-newly-d...](http://www.ascopost.com/.../debate-over-intraperitoneal-chemotherapy-in-newly-d...) ▼ 翻译此页

2018年5月25日 - The hesitancy of **clinicians** to use intraperitoneal therapy **is** likely attributed ... be a biologic **advantage** to the use of **intraperitoneal chemotherapy** in treating ... in 245 **patients** with **advanced** epithelial **ovarian cancer** who **had** at least stable disease after three cycles of **neoadjuvant** carboplatin and paclitaxel.

### Is intraperitoneal chemotherapy still an acceptable option in primary ...

[https://academic.oup.com/annonc/article/28/suppl\\_8/viii40/4693817](https://academic.oup.com/annonc/article/28/suppl_8/viii40/4693817) - 翻译此页

作者: BJ Monk - 2017 - 被引用次数: 9 - 相关文章

2017年12月5日 - The role of **intraperitoneal** (i.p.) **chemotherapy** in treating newly diagnosed ... option in primary **adjuvant chemotherapy** for **advanced ovarian cancer**? .... The pharmacokinetic **advantage** of i.p. therapy **is** particularly evident in ..... cancer due to this new safety and **tolerability** profile with **patient** selection.

### Latest research and clinical treatment of advanced-stage epithelial ...

<https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3786558/> ▼ 翻译此页

作者: RL Coleman - 2013 - 被引用次数: 291 - 相关文章

The role of surgery in the treatment of **ovarian cancer** **is** pivotal to achieve the goal of ... Proponents of **neoadjuvant chemotherapy** **have** cited the improved or at least ... that **is** conducted in **patients** who **have had** a complete **clinical** response to primary treatment ... in the **adjuvant** treatment of **advanced-**

**Name of journal:** *World Journal of Clinical Oncology*

**Manuscript NO:** 45222

**Manuscript Type:** ORIGINAL ARTICLE

*Retrospective Cohort Study*

**Clinical benefit and tolerability of adjuvant intraperitoneal chemotherapy in patients who have or have not received neoadjuvant chemotherapy for advanced ovarian cancer**

Meghal T *et al.* <sup>2</sup> Safety and efficacy of adjuvant intraperitoneal chemotherapy in patients with advanced stage ovarian cancer

Trishala Meghal, Vishangi Dave, Horace Tang, Vivek Kumar, Yiqing Xu

Match Overview

1	<b>Crossref</b> 46 words Claudia Marchetti. "First-line treatment of advanced ovarian cancer: current research and perspectives", Expert Review	1%
2	<b>Crossref</b> 32 words "Poster Session 1", International Journal of Gynecological Cancer, 9/2006	1%
3	<b>Internet</b> 22 words crawled on 03-Sep-2018 providerportal.careimprovementplus.com	1%
4	<b>Internet</b> 16 words crawled on 01-Mar-2019 www.ncbi.nlm.nih.gov	<1%
5	<b>Crossref</b> 10 words Brian Orr, Robert P. Edwards. "Diagnosis and Treatment of Ovarian Cancer", Hematology/Oncology Clinics of North A	<1%
6	<b>Crossref</b> 10 words "abstracts", International Journal of Gynecological Cancer, 9/2004	<1%
7	<b>Crossref</b> 10 words T. Le, H. Latifah, L. Jolicoeur, J. Weberpals, W. Faught, L. Hopkins, M. Fung Kee Fung. "Does intraperitoneal chemothe	<1%





All

Images

Videos

翻译成中文

开启取词

28,600 Results

Any time ▼

## In the Neoadjuvant Era, Intraperitoneal Chemotherapy Is of ...

[www.ascopost.com/issues/june-25-2016/in-the-neoadjuvant-era...](http://www.ascopost.com/issues/june-25-2016/in-the-neoadjuvant-era...) ▼

IP Chemotherapy in Advanced Ovarian Cancer. A randomized phase II study has shown that **adjuvant intraperitoneal (IP) chemotherapy** is superior to **adjuvant intravenous chemotherapy** in advanced ovarian cancer that has been optimally resected. This study was conducted in women treated with neoadjuvant **chemotherapy** first.

## Intraperitoneal chemotherapy in ovarian cancer: a review ...

[www.ncbi.nlm.nih.gov](http://www.ncbi.nlm.nih.gov) › ... › [Cancer Manag Res](#) › v.4; 2012

Nov 23, 2012 · Conclusion. There is level-one evidence suggesting the **benefit** of postoperative **adjuvant intraperitoneal chemotherapy** for patients with **advanced ovarian cancer** after cytoreductive surgery, albeit catheter-related complications resulted after treatment discontinuation.

Cited by: 31

Author: Daniel L Chan, David L Morris, Archana R...

Publish Year: 2012

## Ovarian Cancer - Adjuvant Therapy - Cancer Therapy Advisor

<https://www.cancertherapyadvisor.com/obstetrics-and-gynecology/...> ▼

**Adjuvant chemotherapy** for early stage (stage I and stage II) **epithelial ovarian cancer**. Patients with well- or moderately well-differentiated stage **IA** or **IB** disease have an excellent prognosis and are the only group for whom **adjuvant chemotherapy** has not consistently shown a **benefit**.

## Use and Effectiveness of Intraperitoneal Chemotherapy for ...

[ascopubs.org/doi/full/10.1200/JCO.2015.61.4776](http://ascopubs.org/doi/full/10.1200/JCO.2015.61.4776)

Several randomized **clinical trials** have demonstrated that **intraperitoneal** and **intravenous (IP/IV) chemotherapy** improves survival in women with optimally resected, stage III **ovarian cancer**, compared with **IV chemotherapy** alone.

Cited by: 84

Author: Alexi A. Wright, Angel Cronin, Dana E. M...

Publish Year: 2015

## Phase ii/iii study of intraperitoneal chemotherapy after ...

[www.ncbi.nlm.nih.gov](http://www.ncbi.nlm.nih.gov) › ... › [Curr Oncol](#) › v.18(2); 2011 Apr

Three large randomized **clinical trials** have shown a survival **benefit** in women with stage iii epithelial **ovarian cancer** (eoc) who receive **intraperitoneal (IP) chemotherapy** ...

Cited by: 18

Author: H. J. Mackay, D. Provencheur, M. Heywo...

Publish Year: 2011